中邮证券：政策与热点共振，AI+医疗或迎加速，关注华大智造等标的

新浪财经01-15

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　近日，中邮证券发布研究报告，维持对“AI+医疗”行业“强于大市”的评级，认为该行业在政策与产业共振下正迎来加速发展。华大智造、华大基因、晶泰控股、英硅智能、联影智能、鹰瞳科技等多家行业内企业获关注。　　研报指出，全球AI医疗市场预计将从2022年的137亿美元迅猛增长至2030年的1553亿美元。政策层面，国家多部门...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2603767842?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-15 13:03","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2603767842","market":"us","top_or_hot":-1,"title":"中邮证券：政策与热点共振，AI+医疗或迎加速，关注华大智造等标的","media":"新浪财经","content":"<div>\n<p>炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　近日，中邮证券发布研究报告，维持对“AI+医疗”行业“强于大市”的评级，认为该行业在政策与产业共振下正迎来加速发展。华大智造、华大基因、晶泰控股、英硅智能、联影智能、鹰瞳科技等多家行业内企业获关注。\n　　研报指出，全球AI医疗市场预计将从2022年的137亿美元迅猛增长至2030年的1553亿美元。政策层面，国家多部门...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/marketresearch/2026-01-15/doc-inhhkffr4304773.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中邮证券：政策与热点共振，AI+医疗或迎加速，关注华大智造等标的</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中邮证券：政策与热点共振，AI+医疗或迎加速，关注华大智造等标的\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-15 13:03 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/marketresearch/2026-01-15/doc-inhhkffr4304773.shtml><strong>新浪财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　近日，中邮证券发布研究报告，维持对“AI+医疗”行业“强于大市”的评级，认为该行业在政策与产业共振下正迎来加速发展。华大智造、华大基因、晶泰控股、英硅智能、联影智能、鹰瞳科技等多家行业内企业获关注。\n　　研报指出，全球AI医疗市场预计将从2022年的137亿美元迅猛增长至2030年的1553亿美元。政策层面，国家多部门...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/marketresearch/2026-01-15/doc-inhhkffr4304773.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0251","symbol_name":"专用设备","start_time":0,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-01-15/doc-inhhkffr4304773.shtml","article_id":"2603767842","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603767842","pubTimestamp":1768453380,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　近日，中邮证券发布研究报告，维持对“AI+医疗”行业“强于大市”的评级，认为该行业在政策与产业共振下正迎来加速发展。华大智造、华大基因、晶泰控股、英硅智能、联影智能、鹰瞳科技等多家行业内企业获关注。　　研报指出，全球AI医疗市场预计将从2022年的137亿美元迅猛增长至2030年的1553亿美元。政策层面，国家多部门联合推动“人工智能+制造”，重点鼓励AI在高端医疗装备等场景的应用，为行业注入强心剂。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159891":"医疗","161027":"证券","688114":"华大智造","BK0251":"专用设备"},"translate_title":"China Post Securities: Policies and hot spots resonate, AI + medical care may accelerate, pay attention to targets such as MGI","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159891":1.5,"161027":1.5,"688114":1.5},"content_text":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　近日，中邮证券发布研究报告，维持对“AI+医疗”行业“强于大市”的评级，认为该行业在政策与产业共振下正迎来加速发展。华大智造、华大基因、晶泰控股、英硅智能、联影智能、鹰瞳科技等多家行业内企业获关注。\n　　研报指出，全球AI医疗市场预计将从2022年的137亿美元迅猛增长至2030年的1553亿美元。政策层面，国家多部门联合推动“人工智能+制造”，重点鼓励AI在高端医疗装备等场景的应用，为行业注入强心剂。同时，海外领先企业如TempusAI业绩高增、英伟达与礼来巨额投资共建AI实验室等动向，也强化了全球产业高景气度的预期。\n　　报告分析，AI技术已在制药、辅助诊断、影像手术及医疗服务等多个医疗细分领域步入成熟。在辅助诊断方向，具备高质量数据与技术优势的平台型企业，正利用AI为临床诊断赋能。华大智造、华大基因、润达医疗等公司因在数据与技术方面的优势而被重点关注。\n　　行业普遍认为，在算法、数据与临床场景持续构建闭环的背景下，AI医疗板块已展现出显著优势与增长潜力。\n新浪声明：新浪网登载此文出于传递更多信息之目的，并不意味着赞同其观点或证实其描述。文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：宋雅芳","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603767842","isCrawlerRequest":true}